Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
11.8M
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-7.15M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$5.55M
-
Number of sells
-
-23
Significant Holders of Hepion Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (HEPA) as of Q2 2023
26 filings reported holding HEPA - Hepion Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Hepion Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (HEPA) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 11.8M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include NORTHERN TRUST CORP (0 shares), PNC Financial Services Group, Inc. (0 shares), CITADEL ADVISORS LLC (0 shares), STATE STREET CORP (0 shares), MORGAN STANLEY (0 shares), TWO SIGMA ADVISERS, LP (0 shares), Tower Research Capital LLC (TRC) (0 shares), Federation des caisses Desjardins du Quebec (0 shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (0 shares), and GROUP ONE TRADING, L.P. (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.